AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) shares surged higher on Friday after the company reaffirmed its status as a COVID-19 stock. The company announced that it has been validating the approved COVID-19 antibody test for commercial use in its lab in San Jose, California.
Note that this antibody test previously received the FDA’s Emergency Use Authorization. The validation is expected to be completed in the second half of 2020.
Management noted that as COVID-19 cases are still on the rise and there is no clear short-term containment in sight, COVID-19 tests likely will have both long-term and widespread demand. As such, the company is fully committed to validating the aforementioned approved COVID-19 antibody test.
CEO Chris Yu noted that the pending commercialization of the approved COVID-19 antibody test would be another major new product and service that AnPac Bio offers that would accelerate revenue growth.
AnPac Bio is biotech company focused on early cancer screening and detection with operations in both China and the United States.
As for the stock move, companies tend to get a boost whenever they mention any developments around COVID-19, rather like the similar trend with “blockchain” last year. While AnPac Bio only trades an average of roughly 13,000 shares per day, about 13 million shares had moved in Friday’s session.
Excluding Friday’s move, AnPac Bio stock had lost about 51% year to date, notching a loss of 27% over the past quarter alone.
AnPac Bio-Medical Science stock traded up about 50% to $8.22 on Friday, in a 52-week range of $5.03 to $12.18. The consensus price target is $18.00
24/7 Wall St.Sponsored: Want to Retire Early? Start Here
Want retirement to come a few years earlier than you’d planned? Orare you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
